Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get a rating) to show sales of $187.12 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made earnings estimates for Biohaven Pharmaceutical, with the lowest sales estimate at $171.03 million and the highest estimate at $200.00 million. Biohaven Pharmaceutical reported sales of $43.82 million in the same quarter last year, suggesting a positive year-over-year growth rate of 327%. The company is due to announce its next earnings report on Monday, January 1.
According to Zacks, analysts expect Biohaven Pharmaceutical to record annual sales of $930.94 million for the current year, with estimates ranging from $884.00 million to $965.29 million. For the next fiscal year, analysts expect the company to post sales of $1.38 billion, with estimates ranging from $1.22 billion to $1.46 billion. Zacks sales averages are an average based on a survey of research analysts who cover Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its quarterly results on Friday, February 25. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.07) by ($0.94). The company posted revenue of $190.01 million for the quarter, compared to $175.54 million expected by analysts. In the same quarter last year, the company made ($3.62) earnings per share. Biohaven Pharmaceutical’s revenue for the quarter increased 441.1% compared to the same quarter last year.
Several research companies have recently commented on BHVN. Mizuho raised its price target on Biohaven Pharmaceutical shares from $144.00 to $154.00 and gave the company a “buy” rating in a Thursday, March 3, report. Morgan Stanley lowered its price target on Biohaven Pharmaceutical shares from $148.00 to $146.00 and set an “equal weight” rating for the company in a Wednesday, April 6 report. Three investment analysts gave the stock a hold rating and eight gave the company a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $148.27.
BHVN shares opened at $83.14 on Tuesday. The company has a market capitalization of $5.86 billion, a P/E ratio of -6.36 and a beta of 1.20. Biohaven Pharmaceutical has a 1-year low of $65.24 and a 1-year high of $151.51. The company has a fifty-day moving average of $111.75 and a two-hundred-day moving average of $120.93.
Several hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. FSC Wealth Advisors LLC increased its stake in Biohaven Pharmaceutical shares by 10.0% in Q1. FSC Wealth Advisors LLC now owns 3,300 shares of the company worth $391,000 after buying 300 more shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Biohaven Pharmaceutical in the first quarter worth approximately $477,000. GW&K Investment Management LLC increased its position in Biohaven Pharmaceutical shares by 6.8% in the first quarter. GW&K Investment Management LLC now owns 406,256 shares of the company worth $48,170,000 after acquiring an additional 25,819 shares in the last quarter. The Swiss National Bank increased its position in shares of Biohaven Pharmaceutical by 7.6% in the first quarter. The Swiss National Bank now owns 139,400 shares in the company worth $16,529,000 after acquiring 9,800 more shares last quarter. Finally, Duality Advisers LP bought a new position in shares of Biohaven Pharmaceutical in the first quarter worth approximately $968,000. Institutional investors and hedge funds hold 88.03% of the company’s shares.
About Biohaven Pharmaceutical (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Biohaven Pharmaceutical right now?
Before you consider Biohaven Pharmaceutical, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Biohaven Pharmaceutical didn’t make the list.
Although Biohaven Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here